Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 20/20 | 0.61 |
| ▸ | HSP90AA1 | P07900 | 18/20 | 0.61 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.61 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.49 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4566895 | 0.89 | HSP90AB1 (0.58) | HSP90AB1HSP90AA1HSP90B1TRAP1HDAC3 | |
| SCHEMBL3705341 | 0.89 | HSP90AB1 (0.61) | HSP90AB1HSP90AA1HSP90B1TRAP1HDAC3 | |
| SCHEMBL4566914 | 0.88 | HSP90AB1 (0.58) | HSP90AB1HSP90AA1HSP90B1TRAP1HDAC3 | |
| SCHEMBL3705606 | 0.86 | HSP90AB1 (0.64) | HSP90AB1HSP90AA1HSP90B1TRAP1HDAC3 | |
| SCHEMBL3710687 | 0.85 | HSP90AB1 (0.75) | HSP90AB1HSP90AA1HSP90B1TRAP1HDAC3 | |
| SCHEMBL4566899 | 0.85 | HSP90AB1 (0.54) | HSP90AB1HSP90AA1HSP90B1TRAP1HDAC3 | |
| SCHEMBL4566902 | 0.84 | HSP90AB1 (0.53) | HSP90AB1HSP90AA1HSP90B1TRAP1HDAC3 | |
| SCHEMBL4566919 | 0.82 | HSP90AB1 (0.64) | HSP90AB1HSP90AA1HSP90B1TRAP1HDAC3 | |
| SCHEMBL4566905 | 0.82 | HSP90AB1 (0.64) | HSP90AB1HSP90AA1HSP90B1TRAP1HDAC3 | |
| SCHEMBL14367974 | 0.82 | HSP90AB1 (0.61) | HSP90AB1HSP90AA1HSP90B1TRAP1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150183771-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP (US) | 2015-07-02 | — | — | US | disclosed |
| US-20150183771-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP (US) | 2015-07-02 | — | — | US | disclosed |
| US-8927548-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927548-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8318790-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318790-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20120122869-A1 | TRIZAOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. | 2012-05-17 | — | — | US | disclosed |
| US-20120122869-A1 | TRIZAOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. | 2012-05-17 | — | — | US | disclosed |
| US-20080090887-A1 | Heat Shock Protein 90 (HSP90); treating cancer, inflammatory disorders, angiogenesis inhibition, infections; 3-substituted-4-fused(hetero)aryl-5-phenyl-4H-1,2,4-triazoles | SYNTA PHARMACEUTICALS CORP. | 2008-04-17 | — | — | US | disclosed |
| US-20080090887-A1 | Heat Shock Protein 90 (HSP90); treating cancer, inflammatory disorders, angiogenesis inhibition, infections; 3-substituted-4-fused(hetero)aryl-5-phenyl-4H-1,2,4-triazoles | SYNTA PHARMACEUTICALS CORP. | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122869-A1 | TRIZAOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, CDC37 | HSP90AB1 1/4885HSP90AA1 4/4885HSP90B1 2/4885 |
| US-20080090887-A1 | Heat Shock Protein 90 (HSP90); treating cancer, inflammatory disorders, angiogenesis inhibition, infections; 3-substituted-4-fused(hetero)aryl-5-phenyl-4H-1,2,4-triazoles | HSP90AB1, HSP90AA1, HSP90AB2P | HSP90AB1 1/4885HSP90AA1 2/4885HSP90B1 4/4885 |
| US-20150183771-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | HSP90AB1 1/4885HSP90AA1 3/4885HSP90B1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.